IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the nomination committee has provided their proposal and motivated opinion ahead of the annual general meeting 2021.
In addition to the nomination of
About
For more information
Phone: +46 73 687 64 00
E-mail: daniel.captech@gmail.com
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
About IRLAB
IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se.
https://news.cision.com/irlab-therapeutics-ab/r/irlab-s-nomination-committee-proposes-martin-nicklasson-as-new-board-member-and-provides-their-propo,c3322103
https://mb.cision.com/Main/15440/3322103/1398951.pdf
(c) 2021 Cision. All rights reserved., source